PDS Biotechnology (PDSB) Return on Capital Employed (2015 - 2026)
PDS Biotechnology's (PDSB) quarterly Return on Capital Employed came in at 136.46% in Q4 2025, down 2230.0% YoY from 6.41% in Q4 2024, and down 2.72% on a QoQ basis from 132.84% in Q3 2025.
PDS Biotechnology (PDSB) Return on Capital Employed (2015 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 11 years of Return on Capital Employed data on file, last reported at 136.46% in Q4 2025.
- Quarterly Return on Capital Employed fell 2230.0% year-over-year to 136.46% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 136.46% (down 2230.0% YoY) and the FY2025 annual result came in at 110.9%, down 797.0% from the prior year.
- Return on Capital Employed declined to 136.46% in Q4 2025, from 132.84% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 26.97% in Q3 2021 to a low of 136.46% in Q4 2025.
- A 5-year average of 79.33% and a median of 81.88% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2021 — Return on Capital Employed jumped 8000 bps — and 2023, when it tumbled 5214 bps.
- Tracing PDSB's Return on Capital Employed over 5 years: stood at 32.62% in 2021, then plunged by 93 bps to 63.02% in 2022, then tumbled by 53 bps to 96.39% in 2023, then declined by 18 bps to 114.15% in 2024, then retreated by 20 bps to 136.46% in 2025.
- The last three Return on Capital Employed figures came in at 136.46% (Q4 2025), 132.84% (Q3 2025), and 106.35% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | PDS Biotechnology | 12.08 Mn | 12.08 Mn | - | -397.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -397.83% |
| Dec 31, 2025 | -136.46% |
| Sep 30, 2025 | -132.84% |
| Jun 30, 2025 | -106.35% |
| Mar 31, 2025 | -126.50% |
| Dec 31, 2024 | -114.15% |
| Sep 30, 2024 | -103.24% |
| Jun 30, 2024 | -80.91% |
| Mar 31, 2024 | -88.98% |
| Dec 31, 2023 | -96.39% |
| Sep 30, 2023 | -100.28% |
| Jun 30, 2023 | -82.85% |
| Mar 31, 2023 | -62.12% |
| Dec 31, 2022 | -63.02% |
| Sep 30, 2022 | -48.14% |
| Jun 30, 2022 | -53.43% |
| Mar 31, 2022 | -45.46% |
| Dec 31, 2021 | -32.62% |
| Sep 30, 2021 | -26.97% |
| Jun 30, 2021 | -33.12% |